T family, including both HTLV types I and 11, as well as simian T-cell leukemia virus (STLV) and bovine leukemia virus (BLV), comprise a group of oncovirinae that shares structural and functional characteristics and biologic effects distinct from all other mammalian and avian retroviruses.'4 HTLV-I and BLV are the causative agents of lymphoproliferative disorders referred to as adult T-cell leukemialymphoma (ATLL)' and as enzootic bovine lymphoma (EBL)6 in humans and cattle, respectively. The role of STLV in leukemogenesis in primates is less clear.' HTLV-I is also associated epidemiologically with a neurodegenerative disorder termed HTLV-I-associated myelopathy (HAM)' or tropical spastic paraparesis (TSP)9 in humans.
In contrast, HTLV-I1 has not been linked to a distinct clinical syndrome in humans, and only occasional isolates of this virus have been made.'"."
Limited systematic studies of the seroprevalence of HTLV in the United States have been performed, but such studies are complicated by the fact that enzyme immunoassays, the most widely used screening tests for HTLV antibodies, do not differentiate between infection with HTLV-I and HTLV-II.'2*'3 However, recent evidence suggests that infection with HTLV-I1 may be more widespread than initially suspected, particularly in intravenous drug users (IVDU); in two separate studies of IVDU popula-0006-4971 I91 l7806-0019$3.00/0 inoculated rabbits. Peripheral blood mononuclear cells (PBMC) and other lymphoid cells from HTLV-ll-inoculated rabbits produced minimal p24 in vitro, as determined by enzyme immunosorbent capture assay. Virus was more readily detected by polymerase chain reaction amplification of HTLV-II pol sequences; this occurred most frequently in rabbits inoculated with Mo-T cells, and most frequently in PBMC as compared with other tissues tested (bone marrow, brain, and liver). No evidence of disease occurred in HTLV-IIinoculated rabbits observed for as long as 24 weeks. All control rabbits remained negative for evidence of HTLV-II infection, as determined by the same procedures. These results provide the first evidence of HTLV-II infection in a species other than humans, and demonstrate the usefulness of the rabbit as an animal model t o study the biologic response t o different isolates of this human retrovirus. 0 1991 by The American Society of Hematology.
tions, 36 of 39 and 21 of 23 HTLV-infected individuals were confirmed by polymerase chain reaction (PCR) to be infected with HTLV-II.'4*'5 In addition, HTLV-I1 infection has been documented in a population of Guaymi Indians in PanamaI6; this represents the first description of HTLV-I1 infection outside of traditional risk groups.
The known pathogenicity of HTLV-I and the high seroprevalence of HTLV-I1 in certain risk groups justifies additional study of these human retroviruses. This should include the identification of appropriate auimal models to study the pathogenesis, prevention, and treatment of the infection and disease. Previous work has shown that rabbits can be infected with HTLV-I by the intravenous, intraperitoneal, and oral routes with HTLV-I-infected lymphoid cells of human or rabbit origin."-'' In addition, Miyamoto et a1 recently demonstrated the in vitro transformation of rabbit leukocytes cocultured with an HTLV-11-infected human T-cell line." However, to date, infection with HTLV-I1 in vivo has not been reported in any species other than humans. The purpose of the present study was to determine if rabbits were susceptible to infection with HTLV-I1 in vivo, and to determine if different HTLV-I1 isolates caused different biologic response patterns in this animal model similar to emerging findings with HTLV-I (Lairmore et al, submitted for publication, 1991).
MATERIALS AND METHODS
Rabbits and HTLV-II-infected and control cell inocula. Weanling (8-week-old) specific-pathogen-free New Zealand White rabbits were obtained from a commercial rabbitry (Western Oregon Rabbit Co, Philomath, OR). Groups of rabbits were inoculated intravenously with 1.5 x lo7 to 10 x lo7 HTLV-11-infected cells or uninfected cells as shown in Table 1 . HTLV-11-infected cells were 88% to 98% infected, as determined by fluorescent antibody assay using an HTLV-1/11 anti-p24 monoclonal antibody (MoAb)." In addition, soluble p24 antigen was quantified in 3-day culture supernatants (1 x 106 cellslml) of each cell line (except Mo-T) using an antigen capture enzyme immunosorbent assay (Coulter Immunology, Hialeah, FL). The range of p24 detected was 255 to 375 ng/mL. Control uninfected cells were negative by the same techniques. All cells were lethally irradiated (55 Gy) before inoculation and effectiveness of the irradiation was verified by Serologic and clinicopathologic responses to HTL V-II. All HTLV-11-inoculated rabbits produced antibodies against HTLV-I1 within 2 to 4 weeks PI and remained persistently seropositive over the 12-to 24-week period of study. All control-inoculated rabbits remained seronegative ( Table  2 ). The earliest and strongest HTLV-I1 seroreactivity occurred against p24 antigen in rabbits inoculated with each HTLV-I1 isolate. WIB-detectable seroreactivity to other HTLV-I1 gag (p21, pr53) and env (gp46) antigens occurred later, with less intensity, or not in all inoculated rabbits ( Table 2 and Fig 1) . Reactivity to gp61/68 was not evident by WIB. The time of onset, intensity, and pattern of seroreactivity varied with the HTLV-11-infected cell line used for inoculation. The earliest and most intense reactivity occurred in rabbits inoculated with G12.1 cells (Fig 1) . No evidence of disease was observed in HTLV-IIinoculated rabbits studied through 24 weeks PI, as evidenced by differences in weight gains, hematologic profiles, or the gross or microscopic appearance of tissues between HTLV-11-inoculated and control-inoculated rabbits.
HTLV-11 antigen production from cultured cells. There was no clear difference in HTLV p24 Antigen present in supernatants collected after 3,7, or 14 days of culture. Low levels of antigen were" detected only in rabbits inoculated with G12.1 cells; supernatants of PBMC from two of four rabbits tested at 4 weeks PI, and of spleen cells from one of two rabbits each tested at 4 weeks and 12 weeks PI contained 10 to 12 pg/mL HTLV p24 (data not shown). Levels of HTLV p24 antigen in other culture supernatants from other rabbits inoculated with other HTLV-11-infected cells or control cells were below cutoff levels.
Detection of HTLV-IIprovirus in tissues. A summary of the detection of PCR-amplified HTLV-I1 pol sequences in tissues of rabbits is shown in Table 3 and a representative Southern blot of the amplified products is shown in Fig 2. The PCR-amplified pol product was most frequently detected in PBMC from rabbits inoculated with Mo-T cells (three of four rabbits), and was distributed in multiple tissues of these rabbits (two of three bone marrows tested, one of four brains tested, and two of four livers tested). Interestingly, the most extensive PCR-amplifiedpol reactivity was derived from one rabbit (R841) among those inoculated with 729pH6neo cells containing a molecular clone of HTLV-II,, (Fig 2) . PBMC were collected from all rabbits at 4, 12, and 24 weeks postinoculation (PI), and single cell suspensions of spleen, bone marrow, and mesenteric lymph node were prepared from rabbits killed at each of these intervals. Cells were cultured at a concentration of 1 x 106/mL in RPMI 1640 with 10% fetal bovine serum, 100 U/mL penicillin, and 100 pg/mL streptomycin, 2 mmol/L glutamine, 5 pg/mL phytohemagglutinin (PHA-M; Difco Labs, Detroit, MI), and 10% human interleukin-2 (IL-2; Advanced Biotechnologies Inc, Silver Spring, MD). Aliquots of culture supernatant were collected at 3, 7, and 14 days and tested for the presence of HTLV-I1 antigens by enzyme immunosorbent capture assay.I6 Briefly, supernatant was added to wells of microtiter plates precoated with a murine anti-HTLV-1/11 p24 MoAb (Coulter Immunology). Retention of p24 by the capture antibody was subsequently detected by the addition of biotinylated human anti-HTLV-1/11 antiserum, followed by a strepavidinhorseradish peroxidase complex and chromagen. Absorbance values were determined and compared with a standard curve prepared with known amounts of core protein p24 in the same assay.
Serial samples of PBMC and other tissues collected at necropsy were assayed for HTLV-I1 by PCR as previously described" with minor modifications, using primers and probe specific for the HTLV-I1 pol region?' Briefly, each PCR amplification was performed using 1 pg genomic DNA (approximately 150,000 cells) in a 100 +L reaction volume. The amplification consisted of 34 repetitive three-step cycles with the following conditions: 25°C to 95T, and then 2 minutes each at 95"C, SYC, and 72°C per cycle in a thermal cycler (Perkin-Elmer Cetus, Norwalk, CT). The amplified products were electrophoresed on 1.8% agarose gels, transferred to nylon membranes, and hybridized with a "P-labeled oligonucleotide probe.
Detection of HTLV-II antigens.
Detection of HTLV-II provirus.
DISCUSSION
The results of this study show the infectious transmission of HTLV-I1 in rabbits and represent the first evidence of HTLV-I1 infection in vivo in a species other than humans. Further, the results suggest that rabbits infected with different isolates of HTLV-I1 express different biologic response patterns, which may be due at least in part to heterogeneity amongst the viral isolates. Finally, the demonstration of the in vivo infectivity of a molecular clone of HTLV-I1 provides a mechanism to map the viral genetic determinants responsible for different biologic responses in rabbits.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From In vivo infectivity was evidenced by an early (as early as 2 weeks PI) and persistent (as late as 24 weeks PI) anti-HTLV antibody response and demonstration of viral antigens or amplifiable proviral sequences in tissues of inoculated rabbits. Similar to findings in HTLV-infected h~m a n s , '~.~ the earliest and most intense serologic reactivity occurred against p24 antigen as determined by WIB. Seroreactivity to env (gp46) antigens was also detectable, despite the difficulties in using the WIB technique to detect envelope antibodies due to the expected loss of envelope viral components during antigen purification." The presence of antibodies to both p24 and gp46 in our rabbits met the criteria established by the US Public Health Service for serologic confirmation of HTLV infe~tion.'~ As compared with similar studies with HTLV-1'' (Lairmore et al, submitted for publication, 1991), the HTLV-I1 isolates tested appear to be less infectious and to replicate less efficiently in rabbits. Only low levels of HTLV-I1 antigen were detected in supernatants of short-term cultures of lymphoid cells, and only from 50% of rabbits inoculated with G12.1 cells. Since these studies were conducted, we have discovered that the sensitivity of the antigen detection technique can be increased by coculturing infected cells with normal mitogen-stimulated rabbit lymphoblasts. This modification of the technique should increase the value of data derived in future studies. Gene amplification by PCR provided a greater ability to detect the presence of virus in tissue. Of the tissues tested (including PBMC, bone marrow, brain, and liver), provirus was most readily detected in PBMC. These results parallel those of Miyamoto et al, in which HTLV-I1 were demonstrated by PCR, but not by indirect fluorescence, in in vitro HTLV-11-transformed rabbit leukocytes.*"
No clinicopathologic evidence of disease was detected in HTLV-11-infected rabbits observed for as long as 24 weeks PI in this study, similar to results with HTLV-11-infected rabbits." The absence of disease in HTLV-infected rabbits parallels the situation that occurs in the vast majority of HTLV-infected humans.26 It is possible that as increased numbers of HTLV-infected rabbits are studied for extended periods, disease may become apparent. Furthermore, it is possible that other viral isolates or cofactors are required for the development of disease in HTLV-infected rabbits, again paralleling the potential importance of these considerations in humans.
The biologic response pattern of HTLV-11-infected rabbits varied depending on the viral isolate used for inoculation. This variation included the time of onset and pattern of antiviral antibody response and the frequency, distribution, and intensity of PCR amplifiable proviral sequences in tissues. The earliest seroconversion and the most intense seroreactivity occurred in rabbits infected with G12.1 cells, while provirus was most frequently detected in all tissues tested from rabbits infected with Mo-T cells. It is unlikely that these differences were due to differences in amount of virus administered, because all inocula contained approximately the same number of infected cells. However, the results may be explained by heterogeneity among the isolates, including properties such as replication competency, cell/tissue tropism, immunogenicity, or copy number per infected cell. To provide further support for this supposition, additional studies will need to be performed using the same cell typc infected with different HTLV-I1 isolates.
We have reported similar differences in the biological response pattern of rabbits infected with different isolates of HTLV-I, but we have becn unable to correlate these differences with disease expression in patients from which the isolates were derived (Lairmore et al. submitted for publication, 1991). To date, few structural differences have been described between HTLV-I isolates derived from patients with ATLL and those with HAM/TSP; however, this remains an incompletely studied and a potentially important mcchanism for explaining the variable disease outcome in HTLV-infected patients.
Infectious molecular clones will be required for cxpcrimcnts to unambiguously map the genetic determinants responsible for spccific biologic activities. It is important and encouraging to notc, thcrcforc. that thc 729pH6nco ccll linc, which contains a molecular clonc dcrivcd from thc Mo-T isolatc of HTLV-11, was infectious for rabbits.
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